Key result
Extended epoetin alfa dosing every 2-4 weeks maintained hemoglobin ≥11.0 g/dl in 76.0-89.5% of patients vs 93.5% with weekly dosing, with Q2W and Q4W being statistically non-inferior.
Why the study?
Does extended epoetin alfa dosing (up to every 4 weeks) maintain hemoglobin levels as effectively as weekly dosing in patients with anemia of chronic kidney disease?
RCT (n=519)
Open-label
randomized
Does extended epoetin alfa dosing (up to every 4 weeks) maintain hemoglobin levels as effectively as weekly dosing in patients with anemia of chronic kidney disease?
Extended epoetin alfa dosing schedules of up to once every four weeks are effective and safe for maintaining hemoglobin levels in patients with anemia of chronic kidney disease not on dialysis.
No takes yet. Share an insight, caveat, or question.
Extended epoetin alfa dosing up to every 4 weeks maintains Hb noninferior to weekly; extends maintenance options for stable nondialysis CKD anemia.
Provenzano et al. (2005) conducted an RCT in anemia of chronic kidney disease (n=519). Epoetin alfa vs. 10,000 U once weekly was evaluated on mean final Hb measurements. Extended epoetin alfa dosing every 2-4 weeks maintained hemoglobin ≥11.0 g/dl in 76.0-89.5% of patients vs 93.5% with weekly dosing, with Q2W and Q4W being statistically non-inferior.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: